Generalized pustulosis and severe tubulointerstitial nephrophaty as manifestations of carbamazepine hypersensitivity syndrome by Moreno Ramírez, David et al.
374 Letters to the Editor
growth factor and its receptor mRNA in angiosarcoma.No statistical diVerences were found in serum VEGF
Lab Invest 1995; 73: 859–863.levels between the other angiosarcoma patients (cases
2. Masood R, Cai J, Zheng T, Smith L, Naidu Y, Gill PS.3–11) in whom the p53 gene point mutation was not
Vascular endothelial growth factor/vascular permeability
detected; these patients include those without metastasis factor is an autocrine growth factor for AIDS-associated
(153 ± 70 pgml Õ 1 , range 65–223, n = 4), those with Kaposi’s sarcoma. Proc Natl Acad Sci USA 1997; 94:
metastasis to parotid lymph nodes (166 ± 70 pgml Õ 1 , 979–984.
3. Naka N, Tomita Y, Nakanishi H, Araki N, Hongyo T,range 62–244, n =6), and those with remote metastasis
Ochi T, et al. Mutation of p53 tumor-suppressor gene in(119 ± 101 pgml Õ 1 , range 7–269, n =7) (Fig. 1).
angiosarcoma. Int J Cancer 1997; 71: 952–955.Because of serious heart failure, the patient who had
4. Masuzawa M, Fujimura T, Hamada Y, Fujita Y, Hara H,
detectable p53 gene point mutation (case 1) was treated Nishiyama S, et al. Establishment of a human hemangiosar-
with local radiation therapy alone. The other patients coma cell line (ISO-HAS). Int J Cancer 1999; 81: 305–308.
were treated with surgery, radiation therapy, local or 5. Amo Y, Masuzawa M, Hamada Y, Takasu H, Fujimura
T, Katsuoka K, et al. Serum levels of vascular endothelialsystemic administration of recombinant interleukin-2
growth factor in a hemangiosarcoma patient with a new-(IL-2), and immunotherapy using IL-2 and IL-2-
typed p53 gene point mutation. Br J Dermatol 2000; 143:activated lymphocytes. The eVect of these treatments
1118–1119.may have contributed to the serum VEGF levels. 6. Amo Y, MasuzawaM, Hamada Y, Katsuoka K. Expression
Therefore, serum VEGF levels may not be correlated of vascular endothelial growth factor in a human heman-
with clinical course in most cases of angiosarcomas giosarcoma cell line (ISO-HAS). Arch Dermatol Res 2001;
without p53 gene mutation. 293: 296–301.
7. Hollstein M, Sidransky D, Vogelstein B, Harris SR. p53
mutations in human cancers. Science 1991; 253: 49–53.
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Sir, severely aVected, accompanied by mild oedema. A large
number of pinhead-sized pustules were observed on herAnticonvulsant hypersensitivity syndrome (AHS) is a
multisystemic disorder with cutaneous changes and typ- face and upper back with an intensely erythematous
skin (Fig. 1). A biopsy taken from these pustular lesionsical blood abnormalities that may be triggered by any
of the aromatic antiepileptic drugs (1, 2). We present revealed follicular and non-follicular intraepidermic
spongiform pustules, with a perivascular in ltration ofthe case of a patient who, following carbamazepine
treatment, developed AHS with major cutaneous and lymph cells and eosinophils in the upper dermis.
Vasculitis was absent. These histological changes weresystemic manifestations that are not common in the
consistent with an acute generalized exanthematouscontext of this syndrome.
pustulosis.
Systemic examination revealed a deteriorated overallCASE REPORT
condition of the patient, fever, hepatomegaly and swol-
A 26-year-old woman was referred to our department len bilateral inguinal lymph nodes. The  rst laboratory
for evaluation of a 10-day history of malaise, fever of tests disclosed eosinophilia (13.5%) and elevated
up to 40°C and a generalized exanthem. The patient liver function tests: aspartate aminotransferase 63U/l
had been on carbamazepine therapy (400mg daily) for (0–37U/l ), alanine aminotransferase 262 U/l (0–
1 month because of temporal epileptic seizures. She 40U/l ) and gamma glutamyltranspeptidas e 335U/l
reported no previous history of drug allergies. (11–49U/l ).
Examination revealed a red-violet exanthem involving In view of the clinical and histological changes, we
considered the case to be related to carbamazepine, sothe trunk, extremities, palms and soles; the face was
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patient was  nally discharged from hospital 30 days
after admission.
Once completely recovered, the patient was patch-
tested with carbamazepine 0.1%, 1% and 10% in pet-
rolatum, showing positive results. Seven months later,
she developed a morbiliform exanthem after 4 weeks of
treatment with phenytoin, but on this occasion the
eruption disappeared with no systemic involvement after
withdrawal of the drug.
DISCUSSION
DiVerential diagnosis of generalized pustular eruptions
in adults includes subcorneal pustular dermatosis, eos-
inophilic pustular folliculitis, pustular psoriasis and
acute generalized exanthematous pustulosis, among
others.
AHS is one of the adverse eVects of aromatic antiepi-
leptic drugs such as phenytoin, carbamazepine, pheno-
barbital and primidone. Most cases have been related
to phenytoin and carbamazepine because they are more
widely used (1, 2). The true incidence of this syndrome
is not well established because of the lack of reliable
diagnostic criteria. Nevertheless, among patients on
carbamazepine treatment the incidence may range from
1:1000 to 1:10 000.
Although the pathogenesis is not well understood, the
most accepted hypotheses suggest the inability of these
patients to detoxify certain oxides, which are formedFig. 1. Mild facial oedema with pustules, erythema and desquamation.
from the metabolism of anticonvulsants . Constitutional
factors, HHV-6 infection and a speci c T-cell response,
are also being discussed as possible pathogenic mechan-the treatment was discontinued and the patient was
admitted for observation. The disease did not evolve isms (3).
AHS clinical manifestations usually start 2 to 8 weeksfavourably, renal impairment developing into severe
renal failure within a few days: creatinine 12.1mg/dl after the initiation of anticonvulsant therapy and consist
of fever, skin rash, lymphadenopathy , hepatopathy and(0.7–1.4mg/dl ) and urea 121mg/dl (18–38mg/dl ).
Urinalysis showed proteinuria (100mg/dl ), leucocyturia eosinophilia (4, 5). Cutaneous changes are present in
up to 87% of the patients with AHS, and usually consistand microhematuria. Serologic tests for ANA, antiDNA
and ANCA antibodies were all negative. A renal biopsy of a morbiliform exanthem, although some cases of
exanthematous pustulosis have been reported (1, 4).disclosed an acute tubulointerstitial nephritis with no
involvement of glomeruli or vascular structures, and Fever is the most common systemic complaint and the
liver is the internal organ most frequently aVected inwith no immune deposits on direct immuno- uores-
cence. Therapy with oral prednisone followed by this syndrome, with an incidence of 100% and 51%,
respectively. Hepatic changes range from transitory highintravenous methylprednisolone was administered,
but oliguric renal failure was severe enough to require transaminase levels to fulminant hepatic failure. This
patient showed the mildest form of liver impairment.hemodialysis. Renal function gradually improved,
allowing discontinuation of dialysis treatment. Her Renal involvement is not common, but when it is present
a prerenal failure secondary to hypovolaemia is the mostrecovery was complete 4 weeks later.
The liver and cutaneous symptoms resolved more frequent clinical feature. Our patient developed severe
parenchymatous renal failure which, although notsatisfactorily, with complete remission 10 days after
admission. Nevertheless, the patient developed a wide- common, has been described in isolated cases of AHS
(1, 2, 6).spread exfoliation in the  nal stage of the cutaneous
disease, and numerous micropurpuric lesions on her Treatment consists of discontinuing the suspected
drug, regulation of nutritional and  uid imbalance and ngertips. A biopsy specimen taken from these microp-
urpuric lesions revealed non-speci c perivascular derma- the management of possible complications, which in
this patient even required haemodialysis. Unlike ourtitis with no deposits on direct immuno- uorescence.
These non-speci c lesions spontaneously faded and the case, the prognosis is good for most patients, with
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spontaneous healing a few weeks after withdrawal of REFERENCES
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Sir,
Idiopathic hypereosinophilic syndrome (IHS) is charac-
terized by persistent eosinophilia (above 1.5 ´ 109/l for
more than 6 months) of unknown origin in association
with dysfunction of one or more organs due to tissue
in ltration by eosinophils (1). Cutaneous, cardiac, neur-
ologic and/or pulmonary manifestations are often
observed. Among the skin lesions, erythroderma is a
rare complication of IHS and has only been reported in
a few cases (2–6).
CASE REPORT
In December 1994, a 67-year-old man with no history
of atopy or current medication was referred due to
severely itching erythroderma of a few weeks’ duration
(Fig. 1), small bullae on the upper limbs (Fig. 2), a
palmo-plantar keratoderma and slight edema of the
skin. White cell count was 12.2 ´ 109/l with 9% eosino-
phils (1.1 ´ 109/l, normal range 0–0.5). A skin biopsy
showed non-speci c, mild vasculitis with eosinophils
Topical treatment was not suYciently eVective but pred-
nisone (1mg/kg daily) relieved the skin lesions and
pruritus, with normalization of blood eosinophilia.
Between April 1996 and March 1997 the patient’s symp-
toms relapsed, with blood eosinophilia ranging between
1.5 ´ 109/l and 4.0 ´ 109/l. Short courses of prednisone Fig. 1. Erythroderma with papulous and eczematous lesions. In 1942
temporarily improved the skin lesions. the patient had a plate in his right femur following a fracture. Removal
of the plate did not improve his skin condition.In June 1997 the patient was admitted to our
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